Viridian Therapeutics (VRDN) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Viridian Therapeutics (VRDN) has outperformed Xenon Pharmaceuticals (XENE) over the past year, losing 1.3% versus a loss of 10.0%. Over five years, VRDN leads with a +63.7% price change compared with +35.0% for XENE. Xenon Pharmaceuticals is the larger company by market cap ($3.64 billion vs $3.40 billion), about 1.1 times the size.
Viridian Therapeutics converts more of its revenue into profit, with a net margin of -483.6% versus -4612.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VRDN | XENE |
|---|---|---|
| Share price | $29.96 | $37.04 |
| Market cap | $3.40B | $3.64B |
| 1-day change | -4.71% | -1.38% |
| YTD return | -3.73% | -17.36% |
| 1-year return | -1.25% | -10.01% |
| 5-year return | +63.72% | +34.99% |
| EPS (TTM) | $-3.85 | $-4.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $70.85M | $7.50M |
| Revenue growth (YoY) | +23359.93% | — |
| Net income (latest FY) | $-342.60M | $-345.91M |
| Operating margin | -512.91% | -4974.27% |
| Net margin | -483.57% | -4612.13% |
| 52-week high | $34.29 | $72.66 |
| 52-week low | $13.18 | $33.38 |
| Distance from 52-week high | -12.63% | -49.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +42.72% | +93.55% |
| Average volume | 2.14M | 1.69M |
| Shares outstanding | 113.56M | 98.28M |
| Employees | 252 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Viridian Therapeutics is more profitable, keeping -483.6 cents of every revenue dollar as net income versus -4612.1 cents for Xenon Pharmaceuticals.
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
VRDN vs XENE FAQ
Which is bigger, Viridian Therapeutics or Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) is larger, with a market capitalization of $3.64B compared with $3.40B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, VRDN or XENE?
VRDN returned -1.25% over the past 12 months, compared with -10.01% for XENE (price return, excluding dividends). Past performance does not predict future results.
Are Viridian Therapeutics and Xenon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.